市場調査レポート
商品コード
1379096
非経口栄養市場レポート:栄養タイプ、エンドユーザー、地域別、2023-2028年Parenteral Nutrition Market Report by Nutrient Type (Carbohydrates, Lipid Emulsion, Single Dose Amino Acid Solution, Trace Elements, Vitamins and Minerals), End User ( Hospitals, Clinics, and Others), and Region 2023-2028 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
非経口栄養市場レポート:栄養タイプ、エンドユーザー、地域別、2023-2028年 |
出版日: 2023年11月02日
発行: IMARC
ページ情報: 英文 144 Pages
納期: 2~3営業日
|
世界の非経口栄養剤市場規模は2022年に67億米ドルに達しました。今後、IMARC Groupは、市場は2028年までに99億米ドルに達し、2022~2028年の成長率(CAGR)は6.7%になると予測しています。
非経口栄養(PN)または静脈栄養は、脂肪、タンパク質、ビタミン、ミネラル、炭水化物、電解質などの液体栄養を提供します。これは、消化管を利用できない患者に栄養サポートを提供する専門的な栄養療法の一部です。栄養失調を予防し、エネルギー、水分、体力のレベルを維持するのに役立ちます。その結果、がん、クローン病、短腸症候群、虚血性腸疾患、腸機能異常を患う患者の間で広く使用されています。
栄養不良の有病率の上昇、出生率の増加、未熟児出産の増加が、世界中でPNに対する需要を刺激している主な要因の1つです。さらに、喘息、白血病、結核、気管支炎、水痘、貧血などの小児疾患を患う人の数も大幅に増加しています。このことは、比較的慢性疾患にかかりやすい老人人口の増加とともに、PN製品の需要にもプラスの影響を与えています。さらに、ファストフードの消費の増加は、高血圧、糖尿病、肥満、その他の代謝異常などの非伝染性疾患の増加をもたらしています。これは、肝不全、腎不全、タンパク質・エネルギー栄養失調の罹患率の上昇と相まって、アムニオ酸を豊富に含む非経口製品の消費を増加させています。市場はさらに、脂質エマルションの最適化や間接熱量測定の活用など、PNにおける大幅な改善によって牽引されています。その他にも、各国の行政機関や民間団体によるヘルスケア分野全体の開拓に向けた支出の増加や、ヘルスケア分野でのPN製品の採用率の上昇といった要因もあり、世界全体での市場成長の強化が見込まれています。
The global parenteral nutrition market size reached US$ 6.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 9.9 Billion by 2028, exhibiting a growth rate (CAGR) of 6.7% during 2022-2028.
Parenteral nutrition (PN), or intravenous feeding, offers liquid nutrients like fats, proteins, vitamins, minerals, carbohydrates, and electrolytes. It is a part of specialized nutritional therapy that providing nutritional support to patients who are unable to utilize their gastrointestinal tract. It aids in preventing malnutrition and maintaining energy, hydration, and strength levels. As a result, it is widely used among patients who are suffering from cancer, Crohn's disease, short bowel syndrome, ischemic bowel disease, and abnormal bowel function.
The rising prevalence of malnutrition, growing natality rate, and increasing premature births are among the primary factors catalyzing the demand for PN around the world. Moreover, there is a considerable rise in the number of individuals experiencing pediatric disorders, such as asthma, leukemia, tuberculosis, bronchitis, chickenpox, and anemia. This, along with the rising geriatric population, which is relatively more prone to chronic diseases, is also influencing the demand for PN products positively. Furthermore, the growing consumption of fast food has resulted in the growing instances of non-communicable diseases like hypertension, diabetes, obesity, and other metabolic disorders. This, in confluence with the rising incidences of hepatic insufficiency, renal insufficiency and protein-energy malnutrition, is increasing the consumption of amnio acid-rich and parenteral products. The market is further driven by significant improvements in the PN, such as lipid emulsions optimizations and utilization of indirect calorimetry. Some of the other factors, such as increasing expenditure on the overall development of the healthcare sector by the governing agencies and private entities of several countries and rising adoption of PN products by the healthcare sector, are anticipated to strengthen the market growth across the globe.
IMARC Group provides an analysis of the key trends in each sub-segment of the global parenteral nutrition market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on nutrient type and end user.
Carbohydrates
Lipid Emulsion
Single Dose Amino Acid Solution
Trace Elements
Vitamins and Minerals
Hospitals
Clinics
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Aculife Healthcare Private Limited, B. Braun Melsungen AG, Baxter International Inc., Fresenius SE & Co. KGaA, Grifols S.A., Otsuka Pharmaceutical Factory Inc., Pfizer Inc. and Servona GmbH.